한글목차

단클론항체 치료제 시장 규모는 예측 기간 동안 복합 연간 성장률(CAGR) 14.5%로 추이되며 2024년 2,526억 달러에서 2029년 4,975억 달러 규모로 성장할 것으로 예측됩니다.

단클론 항체 치료제 시장의 견인 요인으로는 만성 질환 증가, 생명 공학의 진보, 표적 치료제에 대한 수요 증가 등이 있습니다. 림프종 치료제인 리툭산(리툭시맙), 자가면역 질환 치료제인 휴밀라(아달리무맙), 암 면역요법제인 키트루다(펨브롤리주맙) 등을 들 수 있으며, 그 효능과 폭넓은 용도에 따라 시장의 성장을 견인하고 있습니다.

제조법별로는 2023년 In-Vitro 부서가 가장 큰 점유율을 차지했습니다.

in-vitro에 의한 제조법의 촉진요인으로는 확장성, 비용 효과, 배치 간의 편차 감소, 규제 준수 등이 있으며, 신뢰성 있고 일관성 있는 바이오 의약품 생산에 대한 수요를 충족하고 있습니다.

유래별로는 인간 유래의 부문이 2023년 최대의 점유율을 차지했습니다.

유래별로는 인간 유래의 부문이 2023년 시장을 독점하였으며 예측 기간중은 인간화 유래의 부문이 높은 복합 연간 성장률(CAGR)로 성장할 것으로 보입니다. 인간 유래 부문의 촉진요인으로는 비인간 유래와 비교하여 면역원성이 저감되고 있는 것, 효능이 향상되고 있는 것, 안전성 프로파일이 개선되고 있는 것 등을 들 수 있습니다.

치료 영역별로는 자가면역,염증성 질환의 부문이 2023년에 최대의 점유율을 차지했습니다.

치료 영역별로는 자가면역 질환 및 염증성 질환 부문이 시장을 독점하고 예측 기간 동안 높은 복합 연간 성장률(CAGR)로 성장할 것으로 예측됩니다. 암 단클론항체 치료제의 고성장, 세계 암 이환율 증가, 표적 치료제의 수용 확대 등의 요인이 성장을 뒷받침하고 있습니다. 또한 지속적인 R&D와 생명공학의 진보도 이 부문의 견조한 성장에 기여하고 있습니다.

본 보고서에서는 세계 단클론항체 치료제 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술,특허 동향, 법규제 환경, 시장 규모 추이와 예측, 각종 구분, 지역별의 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회
  • 과제
• Porter's Five Forces 분석
• 기술 분석
• 밸류체인 분석
• 특허 분석
• 주요 회의 및 이벤트
• 투자와 자금조달 시나리오
• 파이프라인 분석
• 공급망 분석
• 생태계 분석
• 규제 상황
• 가격 분석
• 고객의 비즈니스에 영향을 미치는 동향/혁신
• 주요 이해관계자와 구매 기준

제6장 단클론항체 치료제 시장 : 제조법별

• IN-VITRO 제조
• IN-VIVO 제조

제7장 단클론항체 치료제 시장 : 투여 경로별

• 정맥내 투여 경로
• 피하 투여 경로
• 기타

제8장 단클론항체 치료제 시장 : 유래별

• 인간
• 인간화
• 키메라
• 기타

제9장 단클론항체 치료제 시장 : 치료 영역별

• 염증성 질환 및 자가면역 질환
• 종양
• 혈액
• 안과
• 기타

제10장 단클론항체 치료제 시장 : 최종 사용자별

• 병원
• 장기 케어 시설
• 기타

제11장 단클론항체 치료제 시장 :지역별

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제12장 경쟁 구도

• 주요 기업의 전략/유력 기업
• 수익 점유율 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 기업
• 기업 평가 매트릭스 : 신흥기업/중소기업
• 신흥기업/중소기업 경쟁 벤치마킹
• 단클론항체 치료제 벤더의 평가와 재무 지표
• 브랜드/제품 비교 분석
• 경쟁 시나리오

제13장 기업 프로파일

• 주요 기업
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON SERVICES, INC.
  • MERCK & CO., INC.
  • ABBVIE INC.
  • BRISTOL-MYERS SQUIBB COMPANY
  • ASTRAZENECA
  • SANOFI
  • NOVARTIS AG
  • AMGEN INC.
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • GSK PLC.
  • ELI LILLY AND COMPANY
  • REGENERON PHARMACEUTICALS INC.
  • BIOGEN
  • UCB SA
• 기타 기업
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • Y-MABS THERAPEUTICS, INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • MERCK KGAA
  • KYOWA KIRIN CO., LTD.
  • SWEDISH ORPHAN BIOVITRUM AB
  • UNITED THERAPEUTICS CORPORATION
  • THERATECHNOLOGIES INC.
  • INCYTE
  • SUN PHARMACEUTICAL INDUSTRIES, INC.

제14장 부록

영문목차

The monoclonal antibody therapeutics market is projected to reach USD 497.5 billion by 2029 from an estimated USD 252.6 billion in 2024, at a CAGR of 14.5% during the forecast period.

The driving factors of the monoclonal antibody therapeutics market include increased prevalence of chronic diseases, advancements in biotechnology, and growing demand for targeted therapies. Examples include drugs like Rituxan (rituximab) for lymphoma, Humira (adalimumab) for autoimmune disorders, and Keytruda (pembrolizumab) for cancer immunotherapy, driving market growth through their effectiveness and broad applications.

"The In-Vitro segment accounted for the largest share by production method in 2023."

Based on production method, the monoclonal antibody therapeutics market is segmented into in-vitro and in-vivo. In 2023, in-vitro segment dominated the monoclonal antibody therapeutics market. Driving factors of the in-vitro production method monoclonal antibody therapeutics market include scalability, cost-effectiveness, reduced batch-to-batch variability, and regulatory compliance, meeting demand for reliable and consistent biopharmaceutical production.

"The human segment accounted for the largest share by source in 2023."

Based on source, the monoclonal antibody therapeutics market is segmented into human, humanized, chimeric and other sources. In 2023, human source segment dominated market and humanized segment is likely to grow at significant CAGR during the forecast period. The driving factors of the human source monoclonal antibody therapeutics market include reduced immunogenicity, enhanced efficacy, and improved safety profiles compared to non-human sources. Additionally, advancements in humanization techniques and increased understanding of human immune responses contribute to the growth of this market, catering to diverse therapeutic needs.

"The autoimmune & inflammatory disease segment accounted for the largest share by therapy area in 2023."

The monoclonal antibody therapeutics market is segmented into autoimmune & inflammatory disorders, Oncology, Hematology, opthalmology and other therapy area. In 2023, autoimmune & inflammatory diseases dominated the monoclonal antibody therapeutics market. Cancer segment is anticipated to grow at significant CAGR during the forecast period of 2024-2029. The high growth cancer monoclonal antibody therapeutics is propelled by increasing incidences of cancer globally, coupled with growing acceptance of targeted therapies. Continuous research and development efforts, along with advancements in biotechnology, contribute to the robust growth trajectory of this segment.

"The Europe is growing at the highest CAGR in the monoclonal antibody therapeutics market during the forecast period of 2024-2029."

North America dominates the monoclonal antibody therapeutics market. Europe, is likely to grow at highest CAGR owing to various factors such as favorable regulatory frameworks, robust healthcare infrastructure, increasing investment in research and development, and rising prevalence of chronic diseases. These elements collectively foster a conducive environment for market expansion and innovation.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%

List of Companies Profiled in the Report:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbvie Inc. (US)
• Johnson & Johnson Services, Inc. (US)
• Merck & Co., Inc. (US)
• Bristol Myers Squibb Company (US)
• AstraZeneca (UK)
• Sanofi (France)
• Novartis AG (Switzerland)
• Amgen Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• GSK plc. (UK)
• Eli Lilly and Company (US)
• Regeneron Pharmaceuticals Inc. (US)
• Biogen (US)
• UCB S.A. (Belgium)
• Boehringer Ingelheim International GmbH (Germany)
• Y-mAbs Therapeutics Inc. (US)
• Teva Pharmaceutical Industries Ltd. (Israel),
• Merck KGaA (Germany)
• Kyowa Kirin Co. Ltd. (Japan)
• Swedish Orphan Biovitrum AB (Sweden)
• United Therapeutics Corporation (US)
• Theratechnologies Inc. (Canada)
• Incyte (US)
• Sun Pharmaceutical Industries Ltd. (India)

Research Coverage:

This research report categorizes the monoclonal antibody therapeutics market by production method (in-vitro and in-vivo), source (human, humanized, chimeric and other sources), therapy area (autoimmune & inflammatory disorders, Oncology, Hematology, opthalmology and other therapy area), route of administration (intravenous, subcutaneous and other route of administration), end user (hospitals, long-term care facilities, and other end user) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and trends influencing the growth of the monoclonal antibody therapeutics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product/service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the monoclonal antibody therapeutics market. Competitive analysis of top players and upcoming startups in the monoclonal antibody therapeutics market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall monoclonal antibody therapeutics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Advancements in biotechnology and genetic engineering, Increasing demand for personalized medicine, Growing product pipeline of innovative mAb therapeutics) restraints (Stringent regulatory approval process and High cost of mAb treatments), opportunities (Innovative therapeutic indications, Rising technological advancements in antibody engineering), and challenges (Rising production costs for mAbs) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the monoclonal antibody therapeutics market
• Clinical Trials: Detail Analysis on the products under clinical trials phase III and phase II&III.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the monoclonal antibody therapeutics market
• Competitive Assessment: are F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), GSK plc. (UK), Eli Lilly and Company (US), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 RESEARCH LIMITATIONS
• 1.5 STAKEHOLDERS
• 1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 1 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
  • FIGURE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
• 2.2 MARKET SIZE ESTIMATION
  • FIGURE 3 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023
  • FIGURE 4 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023
  • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE AG: REVENUE SHARE ANALYSIS, 2023
  • 2.2.1 INSIGHTS FROM PRIMARIES
  • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.2.2 SEGMENT ASSESSMENT (BY PRODUCTION METHOD, SOURCE, ROUTE OF ADMINISTRATION, THERAPY AREA, AND END USER)
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• 2.3 GROWTH RATE ASSUMPTIONS
  • FIGURE 9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: CAGR PROJECTIONS, 2024-2029
  • FIGURE 10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY

• FIGURE 12 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2024 VS. 2029 (USD MILLION)
• FIGURE 13 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)
• FIGURE 14 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY TYPE, 2024 VS. 2029 (USD MILLION)
• FIGURE 15 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
• FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MONOCLONAL ANTIBODY THERAPEUTICS MARKET

4 PREMIUM INSIGHTS

• 4.1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET OVERVIEW
  • FIGURE 17 ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING TO DRIVE MARKET DURING FORECAST PERIOD
• 4.2 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD (2023)
  • FIGURE 18 IN-VITRO PRODUCTION METHOD ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
• 4.3 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 HUMAN SOURCE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
• 4.4 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 21 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2.1 DRIVERS
    • 5.2.1.1 Advancements in biotechnology and genetic engineering
    • 5.2.1.2 Increasing demand for personalized medicine
    • 5.2.1.3 Growing product pipeline of mAb therapeutics
  • FIGURE 22 NUMBER OF ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN US/EU (2012-2023)
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent regulatory approval process
    • 5.2.2.2 High cost of mAb treatments
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Innovative therapeutic indications
    • 5.2.3.2 Rising technological advancements in antibody engineering
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Rising development & production costs
• 5.3 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.3.1 THREAT OF NEW ENTRANTS
  • 5.3.2 THREAT OF SUBSTITUTES
  • 5.3.3 BARGAINING POWER OF SUPPLIERS
  • 5.3.4 BARGAINING POWER OF BUYERS
  • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 CONVENTIONAL PRODUCTION OF MABS
  • 5.4.2 TECHNOLOGICAL ADVANCEMENTS FOR MABS
  • TABLE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: TECHNOLOGY COMPARISON
• 5.5 VALUE CHAIN ANALYSIS
  • FIGURE 23 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN
• 5.6 PATENT ANALYSIS
  • 5.6.1 METHODOLOGY
  • 5.6.2 PATENTS FILED BY DOCUMENT TYPE, 2014-2023
  • TABLE 3 PATENTS FILED, 2014-2023
  • 5.6.3 INNOVATION AND PATENT APPLICATIONS
  • FIGURE 24 TOTAL NUMBER OF PATENTS GRANTED, 2014-2023
  • 5.6.4 TOP APPLICANTS
  • FIGURE 25 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2023
  • FIGURE 26 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014-2023
  • TABLE 4 TOP 10 PATENT OWNERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2013-2023
  • TABLE 5 PATENTS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2023-2024
• 5.7 KEY CONFERENCES & EVENTS
  • TABLE 6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024-2025)
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 PIPELINE ANALYSIS
  • TABLE 7 MONOCLONAL ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE
• 5.10 SUPPLY CHAIN ANALYSIS
  • FIGURE 27 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
• 5.11 ECOSYSTEM ANALYSIS
  • FIGURE 28 MONOCLONAL ANTIBODY THERAPEUTICS ECOSYSTEM
  • 5.11.1 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
  • TABLE 8 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
  • 5.11.2 END USERS OF MONOCLONAL ANTIBODY THERAPEUTICS
  • TABLE 9 MONOCLONAL ANTIBODY THERAPEUTIC END USERS
  • 5.11.3 REGULATORY BODIES FOR MONOCLONAL ANTIBODY THERAPEUTICS
  • TABLE 10 MONOCLONAL ANTIBODY THERAPEUTIC REGULATORY BODIES
• 5.12 REGULATORY LANDSCAPE
  • 5.12.1 REGULATORY ANALYSIS
  • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.13 PRICING ANALYSIS
  • 5.13.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS
  • TABLE 15 AVERAGE SELLING PRICE OF MONOCLONAL ANTIBODY THERAPEUTICS IN US
• 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 29 TECHNOLOGICAL ADVANCEMENTS IN MONOCLONAL ANTIBODY PRODUCTION TO DRIVE MARKET GROWTH
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MABS AMONG TOP TWO END USERS
  • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS
  • 5.15.2 BUYING CRITERIA FOR MONOCLONAL ANTIBODY THERAPEUTICS
  • FIGURE 31 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES
  • TABLE 17 KEY BUYING CRITERIA FOR TOP TWO END USERS

6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD

• 6.1 INTRODUCTION
  • TABLE 18 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
• 6.2 IN-VITRO PRODUCTION
  • 6.2.1 HIGH SCALABILITY AND COST EFFICIENCY TO PROPEL MARKET
  • TABLE 19 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 20 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 21 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 22 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 23 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 24 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 25 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
• 6.3 IN-VIVO PRODUCTION
  • 6.3.1 MINIMAL SIDE-EFFECTS TO SUPPORT MARKET GROWTH
  • TABLE 26 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 27 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 31 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 32 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022-2029 (USD MILLION)

7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

• 7.1 INTRODUCTION
  • TABLE 33 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
• 7.2 INTRAVENOUS ROUTE OF ADMINISTRATION
  • 7.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE FOR MULTIPLE INDICATIONS TO DRIVE MARKET
  • TABLE 34 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 35 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 40 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
• 7.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION
  • 7.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO DRIVE MARKET
  • TABLE 41 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022-2029 USD MILLION)
  • TABLE 47 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
• 7.4 OTHER ROUTES OF ADMINISTRATION
  • TABLE 48 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 49 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 53 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 54 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTESC OF ADMINISTRATION, BY COUNTRY, 2022-2029 (USD MILLION)

8 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE

• 8.1 INTRODUCTION
  • TABLE 55 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
• 8.2 HUMAN SOURCE
  • 8.2.1 REDUCED IMMUNOGENICITY AND IMPROVED EFFICACY TO PROPEL MARKET
  • TABLE 56 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 57 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 58 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 62 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
• 8.3 HUMANIZED SOURCE
  • 8.3.1 ABILITY TO ADJUST SPECIFICITY AND BIOLOGICAL FUNCTIONS TO DRIVE MARKET
  • TABLE 63 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 64 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 69 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
• 8.4 CHIMERIC SOURCE
  • 8.4.1 UTILIZATION OF GENETIC ENGINEERING TECHNIQUES FOR MINIMIZED IMMUNOGENIC RESPONSES TO FUEL MARKET
  • TABLE 70 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 71 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 76 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022-2029 (USD MILLION)
• 8.5 OTHER SOURCES
  • TABLE 77 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 78 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 79 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 82 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 83 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022-2029 (USD MILLION)

9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA

• 9.1 INTRODUCTION
  • TABLE 84 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
• 9.2 INFLAMMATORY & AUTOIMMUNE DISORDERS
  • 9.2.1 RISING DEMAND FOR TARGETED THERAPEUTICS TO DRIVE MARKET
  • TABLE 85 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 90 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 91 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022-2029 (USD MILLION)
• 9.3 ONCOLOGY
  • 9.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
  • TABLE 92 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 97 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 98 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
• 9.4 HEMATOLOGY
  • 9.4.1 RISING INCIDENCE OF THROMBOTIC DISORDERS TO SUPPORT MARKET GROWTH
  • TABLE 99 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 100 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 101 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 103 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 104 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 105 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• 9.5 OPHTHALMOLOGY
  • 9.5.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION TO BOOST DEMAND
  • TABLE 106 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 107 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 108 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 109 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 110 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 111 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 112 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
• 9.6 OTHER THERAPY AREAS
  • TABLE 113 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 114 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 115 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 117 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 118 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022-2029 (USD MILLION)

10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER

• 10.1 INTRODUCTION
  • TABLE 120 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 10.2 HOSPITALS
  • 10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET
  • TABLE 121 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 122 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 123 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 126 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 127 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2029 (USD MILLION)
• 10.3 LONG-TERM CARE FACILITIES
  • 10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING ADVANTAGES TO DRIVE MARKET
  • TABLE 128 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 129 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 130 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 131 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 134 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022-2029 (USD MILLION)
• 10.4 OTHER END USERS
  • TABLE 135 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 141 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)

11 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION

• 11.1 INTRODUCTION
  • TABLE 142 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
• 11.2 NORTH AMERICA
  • FIGURE 32 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT
  • TABLE 143 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 144 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 145 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 146 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 147 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 148 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.2.1 NORTH AMERICA: RECESSION IMPACT
  • 11.2.2 US
    • 11.2.2.1 Rising regulatory approvals for product commercialization to propel market
  • TABLE 149 PRODUCT APPROVALS FOR MAB THERAPEUTICS BY US FDA
  • TABLE 150 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 151 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 152 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 153 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 154 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.2.3 CANADA
    • 11.2.3.1 Rising investments in antibody research to support market growth
  • TABLE 155 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 156 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 157 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 158 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 159 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 11.3 EUROPE
  • FIGURE 33 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT
  • TABLE 160 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 161 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 162 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 163 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 164 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 165 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3.1 EUROPE: RECESSION IMPACT
  • 11.3.2 GERMANY
    • 11.3.2.1 Rising number of clinical trials for mAb therapeutics to drive market
  • TABLE 166 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 167 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 168 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 169 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 170 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3.3 UK
    • 11.3.3.1 Increasing R&D initiatives by pharmaceutical & biotechnology companies to support market growth
  • TABLE 171 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040
  • TABLE 172 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 173 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 174 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 175 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 176 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3.4 FRANCE
    • 11.3.4.1 Favorable reimbursement policies for therapeutic treatments to propel market
  • TABLE 177 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 178 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 179 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 180 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 181 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3.5 ITALY
    • 11.3.5.1 Growth in life sciences industry to boost demand
  • TABLE 182 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 183 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 184 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 185 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 186 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3.6 SPAIN
    • 11.3.6.1 Growing focus on research for biomaterial development to drive market
  • TABLE 187 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 188 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 189 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 190 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 191 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3.7 TURKEY
    • 11.3.7.1 Rising investments in R&D for healthcare infrastructure to support market growth
  • TABLE 192 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 193 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 194 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 195 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 196 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.3.8 REST OF EUROPE
  • TABLE 197 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 198 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 199 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 200 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 201 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)

• 11.4 ASIA PACIFIC
  • TABLE 202 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 203 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4.1 ASIA PACIFIC: RECESSION IMPACT
  • 11.4.2 CHINA
    • 11.4.2.1 Growing preference for precision medicines to propel market
  • TABLE 208 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 209 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 210 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 211 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 212 CHINA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4.3 JAPAN
    • 11.4.3.1 Availability of healthcare insurance and favorable regulatory environment to propel market
  • TABLE 213 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 214 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 215 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 216 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 217 JAPAN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4.4 INDIA
    • 11.4.4.1 Increasing incidence of chronic diseases and high growth in pharma R&D to fuel market
  • TABLE 218 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 219 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 220 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 221 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 222 INDIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 Strategic initiatives by key players to support market growth
  • TABLE 223 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 224 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 225 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 226 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 227 SOUTH KOREA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4.6 INDONESIA
    • 11.4.6.1 Funding initiatives and key product launches to support market growth
  • TABLE 228 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 229 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 230 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 231 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 232 INDONESIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4.7 MALAYSIA
    • 11.4.7.1 Increasing focus on government-funded initiatives for management of chronic ailments to support market growth
  • TABLE 233 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 234 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 235 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 236 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 237 MALAYSIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.4.8 REST OF ASIA PACIFIC
  • TABLE 238 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 239 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 240 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 241 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 242 REST OF ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 11.5 LATIN AMERICA
  • TABLE 243 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 244 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 245 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 246 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 247 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 248 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.5.1 LATIN AMERICA: RECESSION IMPACT
  • 11.5.2 BRAZIL
    • 11.5.2.1 Increasing incidence of chronic & infectious diseases to drive market
  • TABLE 249 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 250 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 251 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 252 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 253 BRAZIL: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.5.3 REST OF LATIN AMERICA
  • TABLE 254 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 255 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 256 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 257 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 258 REST OF LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 11.6 MIDDLE EAST
  • TABLE 259 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 260 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 261 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 262 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 263 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 264 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.6.1 MIDDLE EAST: RECESSION IMPACT
  • 11.6.2 GCC COUNTRIES
  • TABLE 265 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 266 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 267 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 268 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 269 GCC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 270 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Rising prevalence of CVD to support market growth
  • TABLE 271 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 272 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 273 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 274 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 275 SAUDI ARABIA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.6.2.2 United Arab Emirates
      • 11.6.2.2.1 Rising prevalence of diabetes to boost demand
  • TABLE 276 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 277 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 278 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 279 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 280 UNITED ARAB EMIRATES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
    • 11.6.2.3 Other GCC countries
  • TABLE 281 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 282 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 283 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 284 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 285 OTHER GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.6.3 REST OF MIDDLE EAST
  • TABLE 286 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 287 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 288 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 289 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 290 REST OF MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
• 11.7 AFRICA
  • 11.7.1 HIGH INVESTMENTS IN HEALTHCARE R&D TO SUPPORT MARKET GROWTH
  • TABLE 291 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022-2029 (USD MILLION)
  • TABLE 292 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
  • TABLE 293 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022-2029 (USD MILLION)
  • TABLE 294 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022-2029 (USD MILLION)
  • TABLE 295 AFRICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • 11.7.2 AFRICA: RECESSION IMPACT

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • FIGURE 34 STRATEGIES ADOPTED BY KEY PLAYERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET
• 12.3 REVENUE SHARE ANALYSIS
  • FIGURE 35 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2020-2023)
• 12.4 MARKET SHARE ANALYSIS
  • FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
  • TABLE 296 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DEGREE OF COMPETITION
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • FIGURE 37 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2023)
  • 12.5.5 COMPANY FOOTPRINT
  • FIGURE 38 COMPANY FOOTPRINT (15 COMPANIES)
    • 12.5.5.1 Type footprint
  • TABLE 297 TYPE FOOTPRINT (15 COMPANIES)
    • 12.5.5.2 Regional footprint
  • TABLE 298 REGIONAL FOOTPRINT (15 COMPANIES)
• 12.6 COMPANY EVALUATION MATRIX: STARTUP/SME PLAYERS
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 DYNAMIC COMPANIES
  • 12.6.3 RESPONSIVE COMPANIES
  • 12.6.4 STARTING BLOCKS
  • FIGURE 39 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2023)
• 12.7 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
  • TABLE 299 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 300 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS
• 12.8 VALUATION AND FINANCIAL METRICS OF MONOCLONAL ANTIBODY THERAPEUTIC VENDORS
  • FIGURE 40 EV/EBITDA OF KEY VENDORS
  • FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• 12.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 12.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
  • FIGURE 42 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND SOURCE
    • 12.9.1.1 F. Hoffmann-La Roche Ltd.
    • 12.9.1.2 Johnson & Johnson Services, Inc.
    • 12.9.1.3 Merck & Co., Inc.
    • 12.9.1.4 AbbVie inc.
    • 12.9.1.5 Sanofi
  • 12.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
  • FIGURE 43 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY COMPANY AND HUMAN SOURCE
    • 12.9.2.1 AstraZeneca
    • 12.9.2.2 Bristol Myers Squibb Company
    • 12.9.2.3 Novartis AG
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT LAUNCHES & APPROVALS
  • TABLE 301 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2021-JANUARY 2024)
  • 12.10.2 DEALS
  • TABLE 302 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DEALS (JANUARY 2021-JANUARY 2024)
  • 12.10.3 OTHER DEVELOPMENTS
  • TABLE 303 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2021-JANUARY 2024)

13 COMPANY PROFILES

• (Business overview, Products/Services offered, Recent developments & MnM View)**
• 13.1 KEY PLAYERS
  • 13.1.1 F. HOFFMANN-LA ROCHE LTD.
  • TABLE 304 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
  • TABLE 305 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 306 F. HOFFMAN LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 307 F. HOFFMAN LA ROCHE LTD.: DEALS
  • 13.1.2 JOHNSON & JOHNSON SERVICES, INC.
  • TABLE 308 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
  • FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2022)
  • TABLE 309 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 310 JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS
  • 13.1.3 MERCK & CO., INC.
  • TABLE 311 MERCK & CO., INC.: COMPANY OVERVIEW
  • FIGURE 46 MERCK & CO., INC COMPANY SNAPSHOT (2022)
  • TABLE 312 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 313 MERCK & CO., INC.: PRODUCT APPROVALS
  • 13.1.4 ABBVIE INC.
  • TABLE 314 ABBVIE INC.: COMPANY OVERVIEW
  • FIGURE 47 ABBVIE INC.: COMPANY SNAPSHOT (2022)
  • TABLE 315 ABBVIE INC.: PRODUCTS /SERVICES OFFERED
  • TABLE 316 ABBVIE INC.: PRODUCT APPROVALS
  • TABLE 317 ABBVIE INC.: DEALS
  • 13.1.5 BRISTOL-MYERS SQUIBB COMPANY
  • TABLE 318 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
  • FIGURE 48 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2022)
  • TABLE 319 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED
  • TABLE 320 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS
  • TABLE 321 BRISTOL-MYERS SQUIBB COMPANY: DEALS
  • TABLE 322 BRISTOL-MYERS SQUIBB COMPANY: OTHER DEVELOPMENTS
  • 13.1.6 ASTRAZENECA
  • TABLE 323 ASTRAZENECA: COMPANY OVERVIEW
  • FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2022)
  • TABLE 324 ASTRAZENECA: PRODUCTS/SERVICES OFFERED
  • TABLE 325 ASTRAZENECA: PRODUCT APPROVALS
  • TABLE 326 ASTRAZENECA: DEALS
  • 13.1.7 SANOFI
  • TABLE 327 SANOFI: COMPANY OVERVIEW
  • FIGURE 50 SANOFI: COMPANY SNAPSHOT (2022)
  • TABLE 328 SANOFI: PRODUCTS/SERVICES OFFERED
  • TABLE 329 SANOFI: PRODUCT APPROVALS
  • TABLE 330 SANOFI: DEALS
  • 13.1.8 NOVARTIS AG
  • TABLE 331 NOVARTIS AG: COMPANY OVERVIEW
  • FIGURE 51 NOVARTIS AG: COMPANY SNAPSHOT (2022)
  • TABLE 332 NOVARTIS AG: PRODUCTS/SERVICES OFFERED
  • TABLE 333 NOVARTIS AG: PRODUCT APPROVALS
  • TABLE 334 NOVARTIS AG: DEALS
  • TABLE 335 NOVARTIS AG: OTHER DEVELOPMENTS
  • 13.1.9 AMGEN INC.
  • TABLE 336 AMGEN INC.: COMPANY OVERVIEW
  • FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT (2022)
  • TABLE 337 AMGEN INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 338 AMGEN INC.: PRODUCT APPROVALS
  • TABLE 339 AMGEN INC.: DEALS
  • TABLE 340 AMGEN INC.: EXPANSIONS
  • 13.1.10 TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • TABLE 341 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW
  • FIGURE 53 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022)
  • TABLE 342 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS/SERVICES OFFERED
  • TABLE 343 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS
  • 13.1.11 GSK PLC.
  • TABLE 344 GSK PLC.: COMPANY OVERVIEW
  • FIGURE 54 GSK PLC.: COMPANY SNAPSHOT (2022)
  • TABLE 345 GSK PLC.: PRODUCTS/SERVICES OFFERED
  • TABLE 346 GSK PLC.: PRODUCT APPROVALS
  • TABLE 347 GSK PLC.: DEALS
  • TABLE 348 GSK PLC.: OTHER DEVELOPMENTS
  • 13.1.12 ELI LILLY AND COMPANY
  • TABLE 349 ELI LILLY AND COMPANY: COMPANY OVERVIEW
  • FIGURE 55 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
  • TABLE 350 ELI LILLY AND COMPANY: PRODUCTS/SERVICES OFFERED
  • TABLE 351 ELI LILLY AND COMPANY: PRODUCT APPROVALS
  • TABLE 352 ELI LILLY AND COMPANY: DEALS
  • TABLE 353 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS
  • 13.1.13 REGENERON PHARMACEUTICALS INC.
  • TABLE 354 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
  • FIGURE 56 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2022)
  • TABLE 355 REGENERON PHARMACEUTICALS INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 356 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS
  • TABLE 357 REGENERON PHARMACEUTICALS INC.: DEALS
  • 13.1.14 BIOGEN
  • TABLE 358 BIOGEN: COMPANY OVERVIEW
  • FIGURE 57 BIOGEN: COMPANY SNAPSHOT (2022)
  • TABLE 359 BIOGEN: PRODUCTS/SERVICES OFFERED
  • TABLE 360 BIOGEN: PRODUCT APPROVALS
  • TABLE 361 BIOGEN: DEALS
  • 13.1.15 UCB S.A.
  • TABLE 362 UCB S.A.: COMPANY OVERVIEW
  • FIGURE 58 UCB S.A.: COMPANY SNAPSHOT (2022)
  • TABLE 363 UCB S.A.: PRODUCTS/SERVICES OFFERED
  • TABLE 364 UCB S.A.: DEALS
  • TABLE 365 UCB S.A.: PRODUCT APPROVALS
• 13.2 OTHER PLAYERS
  • 13.2.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • 13.2.2 Y-MABS THERAPEUTICS, INC.
  • 13.2.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • 13.2.4 MERCK KGAA
  • 13.2.5 KYOWA KIRIN CO., LTD.
  • 13.2.6 SWEDISH ORPHAN BIOVITRUM AB
  • 13.2.7 UNITED THERAPEUTICS CORPORATION
  • 13.2.8 THERATECHNOLOGIES INC.
  • 13.2.9 INCYTE
  • 13.2.10 SUN PHARMACEUTICAL INDUSTRIES, INC.
• *Details on Business overview, Products/Services offered, Recent developments & MnM View might not be captured in case of unlisted companies.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATIONS OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS